These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29514519)

  • 1. Exploiting mAb structure characteristics for a directed QbD implementation in early process development.
    Karlberg M; von Stosch M; Glassey J
    Crit Rev Biotechnol; 2018 Sep; 38(6):957-970. PubMed ID: 29514519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality.
    Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
    Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process characterization and Design Space definition.
    Hakemeyer C; McKnight N; St John R; Meier S; Trexler-Schmidt M; Kelley B; Zettl F; Puskeiler R; Kleinjans A; Lim F; Wurth C
    Biologicals; 2016 Sep; 44(5):306-18. PubMed ID: 27464992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality by Design: Concept to Applications.
    Swain S; Parhi R; Jena BR; Babu SM
    Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to the application of QbD principles for the development of monoclonal antibodies.
    Finkler C; Krummen L
    Biologicals; 2016 Sep; 44(5):282-90. PubMed ID: 27546184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.
    Razinkov VI; Treuheit MJ; Becker GW
    J Biomol Screen; 2015 Apr; 20(4):468-83. PubMed ID: 25576149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework.
    Junker B; Kosinski M; Geer D; Mahajan R; Chartrain M; Meyer B; Dephillips P; Wang Y; Henrickson R; Ezis K; Waskiewicz M
    PDA J Pharm Sci Technol; 2011; 65(3):254-86. PubMed ID: 22293236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach.
    Simões A; Veiga F; Vitorino C; Figueiras A
    J Pharm Sci; 2018 Oct; 107(10):2653-2662. PubMed ID: 29935297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QbD implementation and Post Approval Lifecycle Management (PALM).
    Ohage E; Iverson R; Krummen L; Taticek R; Vega M
    Biologicals; 2016 Sep; 44(5):332-40. PubMed ID: 27449920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of QbD risk assessment tools and overall risk management.
    Kelley B; Cromwell M; Jerkins J
    Biologicals; 2016 Sep; 44(5):341-51. PubMed ID: 27461127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of experiments (DoE) in pharmaceutical development.
    N Politis S; Colombo P; Colombo G; M Rekkas D
    Drug Dev Ind Pharm; 2017 Jun; 43(6):889-901. PubMed ID: 28166428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile.
    Reid CQ; Tait A; Baldascini H; Mohindra A; Racher A; Bilsborough S; Smales CM; Hoare M
    Biotechnol Bioeng; 2010 Sep; 107(1):85-95. PubMed ID: 20506289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.